Overview

Prevention of Decompensation in Liver Cirrhosis

Status:
Unknown status
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether losartan, an angiotensin II blocker prevents the sodium retention in patients with liver cirrhosis and by that reduces the fluid retention. Moreover is the purpose to asses whether losartan is antifibrotic.
Phase:
Phase 4
Details
Lead Sponsor:
Odense University Hospital
Collaborators:
Else Poulsen Mindelegat
Lundbeck Foundation
University of Southern Denmark
Treatments:
Losartan